A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Seagen Inc.
Pfizer
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
BioNTech SE
Astellas Pharma Inc
Boehringer Ingelheim
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
AstraZeneca
RayzeBio, Inc.
Amgen
Genmab
Dana-Farber Cancer Institute
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
City of Hope Medical Center
AstraZeneca
Zai Lab (Hong Kong), Ltd.
University of Chicago
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Debiopharm International SA
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NRG Oncology
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Inhibrx Biosciences, Inc
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, Irvine
City of Hope Medical Center
RemeGen Co., Ltd.
Amgen
BeOne Medicines
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Washington University School of Medicine
Merck Sharp & Dohme LLC
AstraZeneca
University of Oklahoma
HC Biopharma Inc.
NRG Oncology